Send to a Friend Font Size: Increase Decrease

ESPR and KKR Related Headlines

Mar 3, 2026 06:00AM Esperion to acquire Corstasis for $75 million plus milestones
Mar 3, 2026 06:00AM Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ESPR and KKR Related Press Releases

Mar 3, 2026 06:00AM Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ESPR and KKR Related SEC Filings